NCT03445949 - Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

June 23, 2025

Study Completion Date

June 23, 2027

Conditions

Atrial Fibrillation

Interventions

DRUG

short postimplantation dual antiplatelet therapy

continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device

DRUG

extended postimplantation dual antiplatelet therapy

stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device

DRUG

long-term treatment with a single antiplatelet agent

continuing long-term treatment with single antiplatelet agent

DRUG

6 months treatment with a single antiplatelet agent

continuing single antiplatelet agent up until 6 months

Trial Locations (1)

RECRUITING

National Institute of Cardiology, Warsaw